Moderna, Inc. (MRNA): Price and Financial Metrics


Moderna, Inc. (MRNA)

Today's Latest Price: $58.57 USD

3.02 (-4.90%)

Updated Jul 2 4:00pm

Add MRNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

See all "A" rated Strong Buy stocks

MRNA Daily Price Range
MRNA 52-Week Price Range

MRNA Stock Price Chart Technical Analysis Charts


MRNA Price/Volume Stats

Current price $58.57 52-week high $87.00
Prev. close $61.59 52-week low $11.54
Day low $55.81 Volume 26,544,378
Day high $61.80 Avg. volume 16,925,967
50-day MA $59.95 Dividend yield N/A
200-day MA $31.43 Market Cap 21.74B

Moderna, Inc. (MRNA) Company Bio


Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA


MRNA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

MRNA Latest Social Stream


Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Moderna chief created demanding environment - WSJ

The Wall Street Journal reports that Moderna ([[MRNA]] -6.6%) CEO Stéphane Bancel has nurtured a high-stress environment at the Boston-area biotech, although his intense leadership has transformed the company from tiny startup with only $2M to its name to one of the leaders in the race to a COVID-19 vaccine...

Seeking Alpha | July 1, 2020

Moderna: No track record and an unsparing CEO - The WSJ profiles

via Peter Loftus and Gregory Zuckerman at the WSJIt was only a few months ago when few outside biotech had even heard of Moderna (MRNA), and most in the industry didn't think much of its prospects. Fast forward to now, and many believe the company has the best shot at...

Seeking Alpha | July 1, 2020

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo 0.65%
3-mo 69.08%
6-mo 229.42%
1-year 291.51%
3-year N/A
5-year N/A
YTD 199.44%
2019 28.09%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0221 seconds.